Whitehawk Therapeutics (WHWK) Other Non-Current Liabilities (2020 - 2024)
Whitehawk Therapeutics (WHWK) reported Other Non-Current Liabilities of $202000.0 for Q4 2024, down 48.6% quarter-over-quarter from $393000.0 in Q3 2024.
Whitehawk Therapeutics (WHWK) Other Non-Current Liabilities (2020 - 2024) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 3 years of Other Non-Current Liabilities data on file, last reported at $202000.0 in Q4 2024.
- Other Non-Current Liabilities for Q4 2024 came in at $202000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $202000.0 (changed N/A YoY), and the FY2024 annual result was $202000.0, changed N/A from the prior year.
- Other Non-Current Liabilities eased to $202000.0 in Q4 2024 per WHWK's latest filing, from $393000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $393000.0 in Q3 2024 and troughed at $97000.0 in Q4 2020.
- A 3-year average of $200250.0 and a median of $155500.0 in 2022 frame the typical range for Other Non-Current Liabilities.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 202,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Jun 30, 2022 | 109,000.00 |
| Dec 31, 2020 | 97,000.00 |